The Experts below are selected from a list of 10665 Experts worldwide ranked by ideXlab platform
Claus Garbe - One of the best experts on this subject based on the ideXlab platform.
-
Prognostic factors of melanoma patients with satellite or in-transit Metastasis at the time of stage III diagnosis.
PloS one, 2013Co-Authors: Benjamin Weide, Christine Faller, Petra Büttner, Annette Pflugfelder, Ulrike Leiter, Thomas K. Eigentler, Jürgen Bauer, Andrea Forschner, Friedegund Meier, Claus GarbeAbstract:Prognosis of patients with loco-regional Skin metastases has not been analyzed in detail and the presence or absence of concurrent lymph node Metastasis represents the only established prognostic factor thus far. Most studies were limited to patients already presenting with Skin lesions at the time of initial diagnosis. We aimed to analyze the impact of a broad penal of prognostic factors in patients with Skin metastases at the time of first metastatic spread, including patients with synchronous lesions already present at the time of initial diagnosis, stage I/II patients with loco-regional recurrence and patients initially presenting with Skin Metastasis but unknown primary melanoma. We investigated disease-specific survival of 380 patients treated at our department between 1996 and 2010 using Kaplan Meier survival probabilities and Cox-proportional hazard analysis. Five-year survival probability was 60.1% for patients with Skin metastases only and 36.3% for those with synchronous nodal metastases. The number of involved nodes and a tumor thickness of at least 3 mm had independent negative impact on prognosis. A strong relationship was identified between the risk of death and the number of involved nodes. Neither ulceration nor the timing of the first occurrence of metastases as either in stage I/II patients, at the time of excision of the primary melanoma or initially in patients with unknown primary tumor, had additional effects on survival. Lymph node involvement was confirmed as the most important prognostic factor for melanoma patients with loco-regional Skin Metastasis including those with unknown primary tumor and stage I/II patients with Skin recurrence. Consideration of the tumor thickness and of the number of involved lymph nodes instead of the exclusive differentiation into presence vs. absence of nodal disease may allow a more accurate prediction of prognosis for patients with satellite or in-transit metastases.
-
prognostic factors of melanoma patients with satellite or in transit Metastasis at the time of stage iii diagnosis
PLOS ONE, 2013Co-Authors: Benjamin Weide, Christine Faller, Petra Büttner, Annette Pflugfelder, Ulrike Leiter, Thomas K. Eigentler, Jürgen Bauer, Andrea Forschner, Friedegund Meier, Claus GarbeAbstract:Background Prognosis of patients with loco-regional Skin metastases has not been analyzed in detail and the presence or absence of concurrent lymph node Metastasis represents the only established prognostic factor thus far. Most studies were limited to patients already presenting with Skin lesions at the time of initial diagnosis. We aimed to analyze the impact of a broad penal of prognostic factors in patients with Skin metastases at the time of first metastatic spread, including patients with synchronous lesions already present at the time of initial diagnosis, stage I/II patients with loco-regional recurrence and patients initially presenting with Skin Metastasis but unknown primary melanoma. Patients and Methods We investigated disease-specific survival of 380 patients treated at our department between 1996 and 2010 using Kaplan Meier survival probabilities and Cox-proportional hazard analysis. Results Five-year survival probability was 60.1% for patients with Skin metastases only and 36.3% for those with synchronous nodal metastases. The number of involved nodes and a tumor thickness of at least 3 mm had independent negative impact on prognosis. A strong relationship was identified between the risk of death and the number of involved nodes. Neither ulceration nor the timing of the first occurrence of metastases as either in stage I/II patients, at the time of excision of the primary melanoma or initially in patients with unknown primary tumor, had additional effects on survival. Conclusion Lymph node involvement was confirmed as the most important prognostic factor for melanoma patients with loco-regional Skin Metastasis including those with unknown primary tumor and stage I/II patients with Skin recurrence. Consideration of the tumor thickness and of the number of involved lymph nodes instead of the exclusive differentiation into presence vs. absence of nodal disease may allow a more accurate prediction of prognosis for patients with satellite or in-transit metastases.
John A Heaney - One of the best experts on this subject based on the ideXlab platform.
-
metastatic renal cell carcinoma presenting as a Skin nodule case report and review of the literature
The Journal of Urology, 1994Co-Authors: Chandler J Williams, John A HeaneyAbstract:AbstractCutaneous Metastasis from renal cell carcinoma is unusual. A patient is described who presented with a solitary Skin Metastasis 6 months after unilateral radical nephrectomy for renal cell carcinoma. In most instances, once cutaneous involvement is manifest the disease is widespread and has a poor prognosis. The Skin should be examined during tumor evaluation as part of the physical examination and Skin lesions in patients with renal cell carcinoma should be evaluated aggressively to rule out cutaneous Metastasis.
Benjamin Weide - One of the best experts on this subject based on the ideXlab platform.
-
Prognostic factors of melanoma patients with satellite or in-transit Metastasis at the time of stage III diagnosis.
PloS one, 2013Co-Authors: Benjamin Weide, Christine Faller, Petra Büttner, Annette Pflugfelder, Ulrike Leiter, Thomas K. Eigentler, Jürgen Bauer, Andrea Forschner, Friedegund Meier, Claus GarbeAbstract:Prognosis of patients with loco-regional Skin metastases has not been analyzed in detail and the presence or absence of concurrent lymph node Metastasis represents the only established prognostic factor thus far. Most studies were limited to patients already presenting with Skin lesions at the time of initial diagnosis. We aimed to analyze the impact of a broad penal of prognostic factors in patients with Skin metastases at the time of first metastatic spread, including patients with synchronous lesions already present at the time of initial diagnosis, stage I/II patients with loco-regional recurrence and patients initially presenting with Skin Metastasis but unknown primary melanoma. We investigated disease-specific survival of 380 patients treated at our department between 1996 and 2010 using Kaplan Meier survival probabilities and Cox-proportional hazard analysis. Five-year survival probability was 60.1% for patients with Skin metastases only and 36.3% for those with synchronous nodal metastases. The number of involved nodes and a tumor thickness of at least 3 mm had independent negative impact on prognosis. A strong relationship was identified between the risk of death and the number of involved nodes. Neither ulceration nor the timing of the first occurrence of metastases as either in stage I/II patients, at the time of excision of the primary melanoma or initially in patients with unknown primary tumor, had additional effects on survival. Lymph node involvement was confirmed as the most important prognostic factor for melanoma patients with loco-regional Skin Metastasis including those with unknown primary tumor and stage I/II patients with Skin recurrence. Consideration of the tumor thickness and of the number of involved lymph nodes instead of the exclusive differentiation into presence vs. absence of nodal disease may allow a more accurate prediction of prognosis for patients with satellite or in-transit metastases.
-
prognostic factors of melanoma patients with satellite or in transit Metastasis at the time of stage iii diagnosis
PLOS ONE, 2013Co-Authors: Benjamin Weide, Christine Faller, Petra Büttner, Annette Pflugfelder, Ulrike Leiter, Thomas K. Eigentler, Jürgen Bauer, Andrea Forschner, Friedegund Meier, Claus GarbeAbstract:Background Prognosis of patients with loco-regional Skin metastases has not been analyzed in detail and the presence or absence of concurrent lymph node Metastasis represents the only established prognostic factor thus far. Most studies were limited to patients already presenting with Skin lesions at the time of initial diagnosis. We aimed to analyze the impact of a broad penal of prognostic factors in patients with Skin metastases at the time of first metastatic spread, including patients with synchronous lesions already present at the time of initial diagnosis, stage I/II patients with loco-regional recurrence and patients initially presenting with Skin Metastasis but unknown primary melanoma. Patients and Methods We investigated disease-specific survival of 380 patients treated at our department between 1996 and 2010 using Kaplan Meier survival probabilities and Cox-proportional hazard analysis. Results Five-year survival probability was 60.1% for patients with Skin metastases only and 36.3% for those with synchronous nodal metastases. The number of involved nodes and a tumor thickness of at least 3 mm had independent negative impact on prognosis. A strong relationship was identified between the risk of death and the number of involved nodes. Neither ulceration nor the timing of the first occurrence of metastases as either in stage I/II patients, at the time of excision of the primary melanoma or initially in patients with unknown primary tumor, had additional effects on survival. Conclusion Lymph node involvement was confirmed as the most important prognostic factor for melanoma patients with loco-regional Skin Metastasis including those with unknown primary tumor and stage I/II patients with Skin recurrence. Consideration of the tumor thickness and of the number of involved lymph nodes instead of the exclusive differentiation into presence vs. absence of nodal disease may allow a more accurate prediction of prognosis for patients with satellite or in-transit metastases.
Ethan A Flynn - One of the best experts on this subject based on the ideXlab platform.
-
papillary and follicular thyroid carcinoma metastatic to the Skin a case report and review of the literature
Thyroid, 1998Co-Authors: Elizabeth A Koller, John B Tourtelot, Hon S Pak, Mark W Cobb, John C Moad, Ethan A FlynnAbstract:Cutaneous metastases from thyroid cancers are rare. We report the case of an otherwise asymptomatic 81-year-old woman with an enlarging scalp lesion. Her solitary Skin Metastasis was the presenting feature of thyroid carcinoma. Routine histopathology of the lesion was notable for an atypical clear cell neoplasm. Immunohistochemistry was positive for thyroglobulin. Subsequent resection of the thyroid gland identified separate foci (< 1 cm) for both papillary and follicular carcinoma. Although such immunohistochemical staining has been used previously, it has never been reported to provide the definitive diagnosis for a solitary cutaneous Metastasis from the thyroid. Previous tumors had anatomic features in a clinical context that permitted identification by routine light microscopy. Clear cell features found in the follicular focus of carcinoma in the thyroid suggest that it is the primary. A worldwide literature review reveals that follicular carcinoma has a greater preponderance than papillary carcinoma for cutaneous Metastasis and that the majority of Skin metastases from either papillary or follicular thyroid cancer are localized to the head and neck.
Axel Hauschild - One of the best experts on this subject based on the ideXlab platform.
-
metastatic basal cell carcinoma prognosis dependent on anatomic site and spread of disease
European Journal of Cancer, 2014Co-Authors: Margaret Elizabeth Mccusker, N Bassetseguin, Reinhard Dummer, Karl D Lewis, Dirk Schadendorf, Aleksandar Sekulic, Jeannie Hou, Lisa Wang, Huibin Yue, Axel HauschildAbstract:Purpose: This review provides a description of the epidemiology and survival out- comes for cases with metastatic basal cell carcinoma (mBCC) based on published reports (1981-2011). Methods: A literature search (MEDLINE via PubMed) was conducted for mBCC case reports published in English: 1981-2011. There were 172 cases that met the following criteria: primary BCC located on Skin, Metastasis confirmed by pathology and Metastasis not resulting from direct tumour spread. From these, 100 mBCC cases with explicit information on follow-up time were selected for analysis. Survival analysis was conducted using Kaplan-Meier methods. Results: Among 100 mBCC cases selected for analysis, including one case with Gorlin syn- drome, 50% had regional metastases (RM) and 50% had distant metastases (DM). Cases with DM were younger at mBCC diagnosis (mean age, 58.0 versus 66.3 years for RM; P= 0.0013). Among 93 (of 100) cases with treatment information for metastatic disease, more DM cases received chemotherapy (36.2% versus 6.5% for RM), but more RM cases underwent surgery (87.0% versus 40.4% for DM). Among all 100 cases, median survival after mBCC diagnosis